Second successful Phase 3 trial of MDMA-assisted therapy for PTSD

The second Phase 3, philanthropy-funded, clinical trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD) was published confirming prior positive results from the first Phase 3 trial.  No serious adverse events were observed among the participants. The full data, expected to be published in a peer-reviewed journal later this year, will support a new drug application to be filed with the U.S. Food and Drug Administration10 .